Skip to main content
XERS
NASDAQ Life Sciences

Xeris Q3 Revenue Jumps 44% to $107M; 2026 Guidance Raised, 2030 Target Lifted to $1B+

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.479
Mkt Cap
$1.907B
52W Low
$5.25
52W High
$11.415
52W Position info
119% above low
Off High info
at 52W high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

XERS has more than doubled off its 52-week low of $5.25.

Summary

Xeris reported Q3 2026 revenue of $107.2 million, up 44%, with Recorlev up 93% to $71.5 million and net income of $11.3 million. It raised 2026 revenue guidance to $395–405 million and its 2030 outlook to more than $1 billion.


Key Events · Earnings and Guidance · XERS

  • Q3 Revenue Up 44% to $107.2M

    Total revenue rose to $107.2 million from $74.4 million a year earlier, driven by Recorlev net revenue of $71.5 million, up 93% from $37.0 million.

  • Swing to $11.3M Quarterly Profit

    Net income was $11.3 million versus $0.6 million in Q3 2025; Adjusted EBITDA reached $30.8 million, an improvement of $13.3 million, and gross margin rose to 88% from 85%.

  • 2026 Guidance Raised to $395–405M

    Full-year 2026 total revenue guidance was raised to $395–405 million, against $282.5 million booked in the first nine months of 2026.

  • 2030 Outlook Lifted to $1B+

    The 2030 total revenue outlook was raised to more than $1 billion from approximately $750 million, with Recorlev seen approaching $1 billion in annual net revenue three to four years sooner than previously expected.


Analysis · XERS · Life Sciences

Xeris swung to an $11.3 million quarterly profit from a $0.6 million profit a year earlier, and the growth is concentrated where it matters: Recorlev revenue nearly doubled to $71.5 million as the expanded commercial team converted into prescriptions. Management raised full-year 2026 revenue guidance to $395–405 million and pulled forward its 2030 target to more than $1 billion from roughly $750 million — a much bigger revision than a typical quarterly tweak, and it implies Recorlev alone approaches $1 billion annually three to four years sooner than previously expected. The one blemish is Gvoke, down 14% to $21.7 million on a one-time $4 million gross-to-net adjustment, and SG&A rose 38% to fund the Recorlev build. With $131.1 million of cash and the 2028 convertible notes fully retired in July, the balance sheet no longer forces a financing decision.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, XERS was trading at $11.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $5.25 to $11.42. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

XERS - Latest Insights

XERS
Nov 05, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.67
Real-time Price: $17.00 info
Change: +$4.33 (+34%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 2:22 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $13.17
Real-time Price: $17.00 info
Change: +$3.84 (+29%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $10.75
Real-time Price: $17.00 info
Change: +$6.25 (+58%) info
Market Cap: $3.1B info
XERS
Nov 05, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.48
Real-time Price: $17.00 info
Change: +$6.52 (+62%) info
Market Cap: $3.1B info
XERS
Sep 09, 2026, 8:33 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.43
Real-time Price: $17.00 info
Change: +$8.57 (+102%) info
Market Cap: $3.1B info